Clinical Microbiology Division
Clinical Microbiology Division is involved in various institutional drug discovery programmes with prime focus on Mycobacterium tuberculosis, Leishmania donovani, Gram negative and Gram-positive bacteria. Identification of novel drug like molecules followed by hit to lead optimization is the area of research of our division. The focus of the division is to work on understanding the molecular biology and pathogenesis of M. tuberculosis and L. donovani and use this knowledge in the field of drug discovery.
- Identification of novel chemical scaffolds and drug targets for anti-bacterial, anti-protozoan and anti-tuberculosis activity.
- Identifying host-chemical-modulators that could be exploited for the development of anti-TB drugs by targeting host-pathogenic interactions.
- Explore various aspects of parasitic diseases including mechanism of drug resistance, host-parasite interactions, mechanism of pathogenesis, validation of new drug targets, identification of new chemical entities and proteins as drug and vaccine candidates respectively against L. donovani.
- Establishing new drug discovery platforms for high throughput screen for finding new and potent drugs against the resistant strains of bacterial pathogens.
- Screening of chemical libraries for identification of novel chemical scaffold as anti-infective agent.
- Identification and characterization of novel drug target for drug discovery.
- Cloning, expression and purification of microbial genes.
- Differential expression of microbial genes through q-PCR
Biosafety Level-3 facility
Clinical Microbiology Division encompasses a State-of-the-art Biosafety Level-3 (BSL-3) facility for handling and experimentation with hazard group III pathogens. The facility fully complies with the Biosafety in Microbiological and Biomedical Laboratories (BMBL) guidelines. This facility consists of two in-vitro experimentation labs and one animal handling (mice & guinea pigs) for in-vivo experimentations.
The facility is fully equipped with Biosafety cabinets, incubators, centrifuges, deep freezers, CO2 incubators and has two double door autoclaves for handlings of the hazardous waste generated while working on pathogens.
The facility is well equipped with PCR machines, Real-Time PCR, Electrophoresis systems, Gel Documentation systems, Gene pulsar and other such lab equipment for molecular biology work. PCR amplification, gene cloning, native enzyme purification and differential gene expression are some of the experimentations routinely performed in this facility.
Anti-infective research facility
We are actively working on plant based and synthetic pharmacophores with anti-infective activity against M. tuberculosis, L. donovani, gram negative and gram-positive bacteria. A large collection of bacterial, fungal, protozoan and M. tuberculosis clinical isolates is available for extensive evaluation of compounds.
Testing of 2019 novel coronavirus (2019-nCoV) in human clinical samples
|Mehra Rukmankesh, Rashmi Sharma, Khan A. Inshad, and Nargotra Amit
|Identification and optimization of Escherichia coli GlmU inhibitors: an in silico approach with validation thereof.||European journal of medicinal chemistry, 92, 78-90 (2015)|
|Rani Chitra, Mehra Rukmankesh, Rashmi Sharma, Chib Reena, Wazir Priya, Nargotra Amit, and Khan A. Inshad||High-throughput screen identifies small molecule inhibitors targeting acetyltransferase activity of Mycobacterium tuberculosis GlmU.||Tuberculosis, 95, 664-677 (2015)|
|Kuljit Singh, Krishn Pratap Singh, Asif Equbal, Shashi S. Suman, Amir Zaidi, Gaurav Garg, Krishna Pandey, Pradeep Das and Vahab Ali||Interaction between cysteine synthase and serine O-acetyltransferase proteins and their stage specific expression in Leishmania donovani||Biochimie, 131, 29-44 (2016)|
|Kuljit Singh, Gaurav Garg and Vahab Ali||Current therapeutics, their problems and thiol metabolism as potential drug targets in leishmaniasis||Current Drug Metabolism, 17, 897-919 (2016)|
|Rashmi Sharma, Rani Chitra, Mehra Rukmankesh, Nargotra Amit, Chib Reena, Rajput S. Vikrant, Kumar Sunil, Singh Samsher, Sharma R. Parduman, and Khan A. Inshad||Identification and characterization of novel small molecule inhibitors of the acetyltransferase activity of Escherichia coli N-acetylglucosamine-1-phosphate-uridyltransferase/glucosamine-1-phosphate-acetyltransferase (GlmU)||Applied microbiology and biotechnology, 100, 3071-3085 (2016)
|Rashmi Sharma, Lambu Rao Mallikharjuna, Jamwal Urmila, Rani Chitra, Chib Reena, Wazir Priya, Mukherjee Debaraj, Chaubey Asha, Khan A. Inshad||Escherichia coli N-acetylglucosamine-1-phosphate-uridyltransferase/glucosamine-1-phosphate-acetyltransferase (GlmU) inhibitory activity of terreic acid isolated from Aspergillus terreus.||Journal of biomolecular screening, 21, 342-353, (2016)
|Rashmi Sharma and Khan A. Inshad||Mechanism and Potential Inhibitors of GlmU: A Novel Target for Antimicrobial Drug Discovery.||Current Drug Targets (2016)|
|Kuljit Singh, Vahab Ali, Krishn Pratap Singh, Parool Gupta, Shashi S. Suman, Ayan K. Ghosh, Sanjiva Bimal, Krishna Pandey and Pradeep Das||Deciphering the interplay between cysteine synthase and thiol cascade proteins in modulating Amphotericin B resistance and survival of Leishmania donovani under oxidative stress||Redox Biology, 12, 350-366 (2017).|
|Gaurav Garg, Kuljit Singh and Vahab Ali||Proteomic approaches unravel the intricacy of secreted proteins of Leishmania: An updated review||BBA-Proteins and Proteomics, 1866, 913-923 (2018).|
|Gaurav Garg, Vahab Ali, Kuljit Singh, Parool Gupta, Ashish Ganguly, Amogh Sahasrabuddhe, and Pradeep Das||Quantitative secretome analysis unravels new secreted proteins in Amphotericin B resistant Leishmania donovani||Journal of Proteomics, 207, 103464 (2019).|